Home › Compare › JPTXF vs ABBV
JPTXF yields 1.29% · ABBV yields 3.09%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, JPTXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JPTXF + ABBV for your $10,000?
Japan Petroleum Exploration Co., Ltd., together with its subsidiaries, explores for, develops, produces, and sells oil, natural gas, and other energy resources in Japan and internationally. The company operates 10 domestic oil and natural gas fields in onshore and offshore of Hokkaido, Akita, Yamagata, and Niigata prefectures. It also owns and manages a natural gas pipeline network with a total length of approximately 800 kilometres. In addition, the company is involved in well drilling and engineering contracting business; manufacturing and selling oil products; real estate management and insurance agency activities; sale and contracted transportation of crude oil; recycling of waste oil; and pipeline management and maintenance operations. Further, it engages in the geophysical exploration work contracting and geophysical exploration technology development; geophysical logging and mud logging work contract; exploration, development, and production of tight oil, oil sands, and shale gas; purchase and sale of LNG, petroleum products, etc.; provision of industrial disaster prevention and security services; development of solar, wind, geothermal, biomass, and other renewable energy sources; supply of electric power; manufacture and sale of drilling mud preparations and mud; and operation and commissioning of natural power plants. The company was founded in 1955 and is headquartered in Tokyo, Japan.
Full JPTXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.